Summary:
WHAT’S NEW IN PKU?
Synlogic is conducting a phase 2 open-label clinical research study to evaluate the safety of potential new treatment options for PKU. We’re seeking adult patients with classic PKU to participate in the study.
STUDY DURATION:
- Up to 52-day screening
- 15-day treatment period
- 31-day follow-up period
INVESTIGATIONAL DRUGS
- SYNB1618 and SYNB1934, both modified probiotics
- Designed to break down phenylalanine in the diet
- Given orally as a liquid
- This is the third clinical study of SYNB1618 and second clinical study of SYNB1934
KEY ELIGIBILITY CRITERIA
- Age 18 and up
- Have been diagnosed with classic PKU
- Not currently taking pegylated recombinant phenylalanine ammonia lyase (PALYNZIQ®) (within 1 month of screening)
ALL ELIGIBLE PARTICIPANTS WILL RECEIVE AT NO COST
- Close care and monitoring throughout the study
- Investigational drugs
- All study-related visits
- Compensation for participation, including travel and study-related activities